ROCKET PHARMACEUTICALS, INC. current report, 30 September 2026

Full document

Business context and reporting period

Rocket Pharmaceuticals, Inc. reported on a financing transaction entered into on September 30, 2026. The October 6, 2026 Form 8-K describes a senior secured term loan facility with Hercules Capital, Inc. and related warrants. It does not report quarterly operating results.

Key financial terms

  • Facility size and funding: Up to $150.0 million across five tranches. The initial $35.0 million Tranche 1-A was funded on September 30, 2026. Additional tranches are optional, milestone-dependent, or subject to lender investment committee approval.
  • Interest and repayment: Floating annual rate equal to the greater of prime rate or 6.75%, plus 2.40%. Interest-only payments run through April 1, 2029, with potential extensions tied to milestones and no continuing default; principal and interest are then payable in equal monthly installments.
  • Maturity: October 1, 2030, potentially extendable to October 1, 2031 if the Tranche 2 Milestone is achieved and no default is continuing.
  • Fees and prepayment: Facility fees apply at closing and to subsequent advances. End-of-term charges also apply. Voluntary prepayment charges range from 3% to 1%, depending on timing.
  • Collateral and liquidity covenant: The obligations are secured by a first-priority interest in substantially all borrower assets, including intellectual property, subject to exceptions. A minimum qualified-cash covenant requires cash equal to a specified 35%–75% of outstanding term loans, depending on milestone achievement; it is not tested while market capitalization exceeds $600.0 million. The test date may be deferred based on qualifying equity proceeds.
  • Warrants: Lenders received warrants for up to 1,755,853 common shares at $2.99 per share. Warrants covering 409,699 shares became exercisable after the initial advance; the full warrant amount becomes exercisable only if the full $150.0 million facility is drawn.

The filing does not provide revenue, profit, cash flow, margins, existing debt balances, or a clear value for cash and liquidity available before or after the transaction.

Material changes versus the prior comparable period

This is a current report announcing a new financing arrangement, not a comparative-period financial filing. It provides no prior-period financial figures for comparison. The transaction adds $35.0 million of funded senior secured debt and potential future borrowing capacity, along with possible equity dilution from the warrants.

Outlook, risks, and unusual items

  • Access to later tranches depends on specified availability periods and, for Tranche 2, achievement of a milestone; Tranche 3 is subject to lender approval in its sole discretion.
  • Extensions of interest-only payments and maturity depend on milestones, including an FDA approval-related milestone for RP-A501 for Danon Disease, and on the absence of a continuing default.
  • The agreement includes restrictions on indebtedness, liens, investments, mergers, asset dispositions, distributions, and affiliate transactions, subject to exceptions. Defaults may allow lenders to accelerate repayment and exercise secured-creditor remedies.
  • During an event of default, the interest rate increases by 4.00 percentage points. The loan also carries prepayment charges and end-of-term charges.
  • The warrants were issued in an unregistered transaction under a Securities Act exemption and may be exercised for cash or on a cashless basis.
  • The 8-K notes that a press release and investor presentation concerning the financing and Danon Disease program were furnished as exhibits; their detailed contents are not included in the supplied filing text.

Important facts for investors to verify

  1. Whether and when Rocket draws the optional tranches, and the related fees, interest expense, and end-of-term charges.
  2. The precise milestone definitions and whether they are achieved, particularly the Tranche 2 and RP-A501 approval milestones.
  3. The applicable minimum-cash covenant test date, required cash percentage, and the company’s qualified cash and market capitalization relative to the covenant terms.
  4. The complete Loan Agreement and warrant terms, including omitted portions, and the potential dilution if additional advances are funded and warrants are exercised.
  5. The company’s current cash, burn rate, other debt obligations, and liquidity outlook, which are not stated in this 8-K text.